PlainRecalls
ModerateClass IIOngoing

FDA Drug recall · Reported February 28, 2024

Terlivaz (terlipressin for injection), 0.85mg/vial, Single-Dose Vial, Rx only, Distributed by: Mallinckrodt Hospital Products Inc., Bridgewater, NJ 08807, USA, NDC 43825-200-01

cGMP deviations: Temperature excursion due to shipping delay from manufacturer to distributor. Affected distributor has been notified.

Recall #
D-0341-2024
Affected scope
421 vials involved in this recall (2,448 vials distributed)
Initiated
February 6, 2024
Verify with FDA Drug →
View my saved recalls

Mallinckrodt Hospital Products Inc. recalled Terlivaz (terlipressin for injection), 0.85mg/vial, Single-Dose Vial, Rx only, Distribute… - a moderate-severity action.

Terlivaz (terlipressin for injection), 0.85mg/vial, Single-Dose Vial, Rx only, Distribute… was recalled by Mallinckrodt Hospital Products Inc. in February 28, 2024. Reason: cGMP deviations: Temperature excursion due to shipping delay from manufacturer to distributor. Affected distr…. Check the official notice for the remedy. Verify recall #D-0341-2024 with the FDA Drug before acting.

The recall

Mallinckrodt Hospital Products Inc. issued this moderate-severity FDA Drug recall-cGMP deviations: Temperature excursion due to shipping delay from manufacturer to distributor. Affected distr….

Moderate
severity level
Class II
classification
February 28, 2024
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-0341-2024 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This recall's affected scope, documented in the Recall Profile below, stays within a single-region or limited-distribution footprint. Distribution scope (see Distribution below) directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 6 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Drugs & Medications recalls over time

Where this recall sits in its category - 14,472 drugs & medications recalls on record

05001,0001,5002,000 2006201220152018202120242026 448
Severity1906864652High severity (most serious)Moderate severityLow severity
Where this agency-classified recall sits among FDA Class I/II/III notices

Of 88,244 recalls with an agency hazard classification, 19,068 are high severity, 64,652 moderate, and 4,524 low. A further 16,179 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified moderate severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Product description

Terlivaz (terlipressin for injection), 0.85mg/vial, Single-Dose Vial, Rx only, Distributed by: Mallinckrodt Hospital Products Inc., Bridgewater, NJ 08807, USA, NDC 43825-200-01

Reason for recall

cGMP deviations: Temperature excursion due to shipping delay from manufacturer to distributor. Affected distributor has been notified.

Recall Profile

Structured summary of the FDA Drug recall record
Attribute Value
Agency U.S. Food and Drug Administration
Severity class Moderate (Class II)
Status Ongoing
Recall number D-0341-2024
Date reported February 28, 2024
Date initiated February 6, 2024
Recalling firm Mallinckrodt Hospital Products Inc.
Firm location Bridgewater, NJ
Affected scope 421 vials involved in this recall (2,448 vials distributed)
Distribution USA nationwide

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

  • Check the recall number (D-0341-2024) and product description against the item you own. Search the archive
  • Confirm the current status with FDA Drug before acting, recall details can be updated.
  • Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled?
Terlivaz (terlipressin for injection), 0.85mg/vial, Single-Dose Vial, Rx only, Distributed by: Mallinckrodt Hospital Products Inc., Bridgewater, NJ 08807, USA, NDC 43825-200-01. Recalled by Mallinckrodt Hospital Products Inc.. Units affected: 421 vials involved in this recall (2,448 vials distributed).
Why was this product recalled?
cGMP deviations: Temperature excursion due to shipping delay from manufacturer to distributor. Affected distributor has been notified.
Which agency issued this recall?
This recall was issued by the FDA Drug on February 28, 2024. Severity: Moderate. Recall number: D-0341-2024.
Where was the recalled product distributed?
Distribution: USA nationwide.
Should I stop using a recalled medication or medical device?
Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nationwide recalls with similar severity or category timing

Drug and device notices outside this firm and state, matched by severity timing and product category.

Compare this recall with Kian Pee Wan Capsules, 30-count bottles → · All Drugs & Medications recalls

This recall: FDA Drug, reported February 28, 2024. Severity classes follow each agency's own taxonomy; related-recall context is computed across the full archive.

Methodology · Corrections · Archive as of August 2026